(C) PLOS One [1]. This unaltered content originally appeared in journals.plosone.org.
Licensed under Creative Commons Attribution (CC BY) license.
url:https://journals.plos.org/plosone/s/licenses-and-copyright

------------



Current state of Ebola virus vaccines: A snapshot

['Courtney Woolsey', 'Galveston National Laboratory', 'University Of Texas Medical Branch', 'Galveston', 'Texas', 'United States Of America', 'Department Of Microbiology', 'Immunology', 'Thomas W. Geisbert']

Date: 2022-01 

Citation: Woolsey C, Geisbert TW (2021) Current state of Ebola virus vaccines: A snapshot. PLoS Pathog 17(12): e1010078. https://doi.org/10.1371/journal.ppat.1010078 Editor: Rebecca Ellis Dutch, University of Kentucky, UNITED STATES Published: December 9, 2021 Copyright: © 2021 Woolsey, Geisbert. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This work was supported in part by NIAID/NIH grant number U19AI142785 to TWG. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: TWG is listed as a co-inventor on U.S. patent numbers 7,635,485; 8,017,130; 8,796,013 related to filovirus vaccines and has received no royalties from any filovirus vaccine. CW has declared that no competing interests exist.

Why are Ebola virus vaccines needed? Four species of the genus Ebolavirus cause severe and often lethal disease in humans: Sudan ebolavirus (SUDV), Bundibugyo ebolavirus (BDBV), Taï Forest ebolavirus (TAFV), and Zaire ebolavirus (EBOV) [1]. Historically, EBOV has caused most Ebolavirus outbreaks and cases. The devastating 2013 to 2016 EBOV epidemic in West Africa, resulting in approximately 29,000 cases, prompted the global community to rapidly advance vaccine candidates that were previously in nascent stages of development [2]. The recent reemergence of EBOV in Guinea, Uganda, and the Democratic Republic of Congo (DRC) emphasizes the continued need for safe and effective vaccines against this deadly pathogen along with optimal deployment strategies. Heroic efforts by countless volunteers and organizations to vaccinate contacts of confirmed patients, healthcare staff, and frontline workers helped curb the West Africa epidemic and these more recent flare-ups [3,4]. As the global community was better prepared for the latter, a quick vaccination response was implemented that significantly abated transmission [4]. While EBOV outbreaks have historically impacted relatively small numbers of people on a global scale, they have caused great suffering and have inflicted an enormous economic toll in endemic countries. Demonstrated exportation of the virus to nonendemic regions [2,5] along with the bioweapon potential of ebolaviruses further warrant the development of EBOV vaccines worldwide.

Which immunization strategy or combination of strategies is optimal for controlling Ebola virus infections? The most effective vaccination strategies to prevent EBOV disease should balance benefits and risks to maximize vaccine impact while minimizing global costs, effort, and human suffering. Widespread mass vaccination is not considered an attainable goal as the endemic region includes much of West and Central Africa [2], putting over half of a billion individuals at risk. It is estimated that 80% vaccine coverage would be required to establish herd immunity against EBOV based on 90% vaccine efficacy and an estimated basic reproductive number value (R 0 ; number of secondary cases that result from an individual infection) of 4 [5]. Financial/logistical hurdles and limited vaccine acceptance in the affected regions make such a vaccination rate a challenge. Ring vaccination (immunizing contacts (and contacts of contacts) of confirmed patients) similarly faces logistical barriers: Many EVD contacts cannot be reached or refuse vaccination, limiting its effectiveness [6]. Immunization of select groups also fuels equity concerns. A tailored solution for each situation based on epidemiological characteristics and modeling is the best vaccine strategy. Early contact tracing along with ring vaccination may be adequate for isolated cases and small outbreaks, but supplemental approaches such as geographic- and/or population-based vaccination may be needed to curb large-scale outbreaks, especially if there is a high level of contact inaccessibility [5–7]. The latter vaccination strategies could additionally help foster vaccine trust. Routine immunization of healthcare and frontline workers in endemic regions as well as other specific groups (ambulance drivers, hospital cleaners, and burial teams) may also prove beneficial, as this population is at enhanced risk, and nosocomial transmission has been an amplifying factor in previous outbreaks [7].

Ervebo (rVSV-EBOV; V920) Ervebo is a live-attenuated, replication-competent, single-dose vaccine originally developed and shown to completely protect nonhuman primates (NHPs) by scientists at the Public Health Agency of Canada and the US Army [10]. The recombinant vesicular stomatitis virus (rVSV)-based vaccine expresses a functional full-length EBOV GP instead of the native VSV GP (rVSV-EBOV), thereby narrowing host tropism specifically toward cell targets of EBOV. Despite decades of promising preclinical research in NHPs, clinical development of rVSV-EBOV stalled until the 2013 to 2016 West African epidemic. In the face of the looming crisis, Phase I/II clinical trials were conducted in healthy volunteers in Europe, Africa, and the US in 2014 [8]. A single dose of Ervebo was shown to be highly immunogenic in volunteers, producing robust humoral responses in nearly all recipients. EBOV GP–specific antibody responses were strong after 2 years, indicating that Ervebo is also durable [11]. Adverse effects in vaccinees were typically mild [8]. Following safety and immunogenicity testing, Ervebo was deployed in Guinea for Phase III efficacy evaluation in 2015. Results indicated that the vaccine was “100% effective” as no new cases were identified in the vaccinated population 10 days or more after immunization [3]. As Ervebo proved a resounding success in an outbreak setting, over 300,000 contacts were immunized with Ervebo during the 2018 to 2020 DRC EBOV outbreak [4,5]. According to preliminary results, the vaccine was 97.5% effective at stopping EBOV transmission compared to no vaccination [4]. The vaccine also has potential as an emergency postexposure prophylactic as demonstrated by its use in a laboratory incident [12] as well as several NHP studies [13]. Currently, Ervebo is the only vaccine with proven clinical efficacy and US Food and Drug Administration (FDA) approval. Preexisting immunity to the rVSV vector is of little concern given the low seropositivity in the general population and because immune responses are predominantly directed at the VSV GP, which is absent from the vaccine. For example, previous vaccination of NHPs with a Lassa virus GP precursor-expressing rVSV vaccine did not abrogate immunity when NHPs were sequentially immunized with an EBOV GP–expressing rVSV vaccine and challenged with EBOV [14]. An ultra-cold chain requirement for long-term storage is a disadvantage for Ervebo.

Zabdeno/Mvabea (Ad26-ZEBOV/MVA-BN-Filo) The Zabdeno/Mvabea vaccine employs both AdVac technology and MVA-BN technology and is delivered in 2 doses: Zabdeno (Ad.26.ZEBOV) is administered first, and Mvabea (MVA-BN-Filo) is given approximately 2 months later [8]. Hence, this preventive 2-dose regimen is not suitable for an outbreak response where immediate protection is necessary. The Zabdeno component is derived from adenovirus serotype 26 (Ad26) and expresses the EBOV GP in place of the replication-essential adenovirus early 1 region [15]. Unlike Ervebo, Zabdeno is unable to replicate in humans. While this attribute may be desirable for a preventive vaccine due to its perceived safety profile, much higher doses are required to elicit a protective immune response (approximately 72 million infectious unit (i.u.) dose of Ervebo versus 50 billion i.u. for Zabdeno). The adenovirus surface spike protein is retained in contrast to Ervebo, which expands the target cell repertoire. Because Ad26 is associated with human disease, many individuals may have preexisting immunity against the virus vector (10% to 90% depending on geographic location), particularly in EBOV-endemic regions [16]. Nevertheless, immune responses of Zabdeno/Mvabea-vaccinated subjects were not markedly different between seronegative individuals and those exhibiting baseline Ad26 seropositivity [17]; it is not known whether a subsequent dose or exposure to the same Ad26 vector backbone will impact vaccine effectiveness. The Mvabea component consists of a modified Vaccinia Ankara virus (MVA) encoding GPs from EBOV, SUDV, and Marburg virus (MARV), and TAFV nucleoprotein [15]. A multivalent filovirus vaccine targeting multiple Ebolavirus species such as Mvabea is optimal for preventive administration. While protective efficacy against MARV and other Ebolavirus species has not yet been demonstrated, preclinical studies indicate a Zabdeno/Mvabea prime-boost immunization provided full protection of NHPs against an EBOV challenge [18]. Phase I/II/III clinical trials have demonstrated that Zabdeno/Mvabea is safe and elicits strong neutralizing and nonneutralizing antibody responses in vaccine recipients along with both CD4+ and CD8+ T cell responses [15,17]. During the 2018 to 2020 outbreak, Zabdeno/Mvabea was administered to over 20,000 individuals, with 9,560 receiving the second dose [19]. A population-level Phase III trial evaluating the efficacy of Zabdeno/Mvabea was initiated in DRC, but that data have not yet been reported [16]. Due to the absence of efficacy data, predictive efficacy of Zabdeno/Mvabea for European Medicines Agency (EMA) approval was based on bridging clinical immunogenicity data with efficacy and immunogenicity data in NHPs [15]. The highest protective efficacy for Zabdeno/Mvabea in NHPs was found at a dosing interval of 8 weeks. When given an identical clinical dose at this interval, all animals survived. Briefer dosing intervals provided less protection: 80% at 42 days and 50% to 57% at 28 days. Based on the pooled immunogenicity data from healthy adults, the mean predicted survival probability was estimated at 53.4%. Humoral responses are largely sustained for 2 years but decline to levels >10-fold lower than peak titers. Boosters at approximately 1 year induced anamnestic responses with an approximate 12- to 55-fold increase in EBOV GP binding antibody titers within a week [15]. As the protective threshold of circulating antibodies is not established, one cannot ascertain the level needed to protect humans from EBOV. Nonetheless, all or most boosted NHPs survived when challenged 1.5 years post-primary vaccination. A Zabdeno booster is recommended for individuals at high risk of Ebola virus exposure if their 2-dose vaccine regimen was completed more than 4 months ago.

cAd3-EBOZ (chAd3-EBO Z) with or without MVA-BN-Filo cAd3-EBOZ/MVA-BN-Filo was developed by NIAID/NIH in collaboration with Okairos [8]. The vaccine platform is similar to Zabdeno/Mvabea; however, the first dose consists of an attenuated chimpanzee adenovirus (cAd3). This feature addresses issues associated with preexisting immunity to the vector such as the case with Zabdeno. An optional heterologous booster of multivalent Mvabea is administered as a subsequent dose. Phase I/II clinical trials proved the vaccine to be well tolerated and immunogenic [20–22]. Most adverse events were self-limited and mild, indicating that the vaccine is safe. Strong humoral responses were noted in vaccinees, particularly after the Mvabea booster. Four weeks after immunization with the CAd3 vaccine alone, GP-specific antibody responses were slightly lower yet similar to those induced by Ervebo, but less durable at 12 months [23]. Neutralization antibody activity and injection site reactions were also similar between the 2 vaccines. Human and NHP bridging data predicted protection of 91% of Malian and 60% of US participants given a single high 1 × 1011 infectious particle dose of cAd3-EBOZ based on reciprocal binding antibody levels; a titer of 1,000 or higher is hypothesized to confer high-level protection. A subsequent dose of Mvabea stimulated anamnestic antibody and CD4/CD8 T-cell responses, suggesting that this booster might further boost protection and duration of immunity [23].

What are some other vaccines in clinical development? CanSino and GamEvac vaccines—platforms derived from rVSV- and adenovirus-based technologies—are currently licensed for emergency use in China and the Russian Federation, respectively (Table 1) [24,25]. Another promising EBOV Phase I vaccine candidate is an additional rVSV vector, Vesiculovax (Auro Vaccines), which expresses EBOV GP along with a highly attenuated form of VSV GP [26,27]. Other EBOV vaccine candidates where Phase I trial data have been published include a 2-dose DNA vaccine targeting EBOV [28], a bivalent DNA plasmid vaccine targeting EBOV and MARV [29,30], and a 2-dose monovalent nanoparticle recombinant EBOV GP vaccine [31].

Are there remaining challenges for Ebola virus vaccines? While substantial progress has been made in the development of EBOV vaccines, multiple questions remain unanswered including the following: (1) what is the durability and the immediacy of immune responses generated by different vaccines; (2) what are the specific correlates and thresholds of protection; (3) do any interactions or interferences exist between vaccines and potential therapeutics; (4) what is the safety of these vaccines in special populations, particularly pregnant women and the immunocompromised; and (5) can vaccines be formulated to be stable for long-term storage at 2 to 8°C, which would be useful in endemic areas [8]? Another major hurdle is mitigating the economic risks for manufacturers and distributors of EBOV vaccines since the demand may not be high enough to warrant stockpiling. Outbreaks also tend to occur in resource-poor countries leaving little financial incentive for commercial development. In January 2021, the International Coordinating Group (ICG) comprised of public and private benefactors established an Ebola vaccine stockpile in Sweden with the goal of manufacturing 500,000 doses. Stockpiling is an important step toward controlling EBOV outbreaks as it is critical for ensuring timely access to vaccines for at-risk populations [32]. Lastly, the most advanced vaccines are solely indicated for protection against one species of Ebolavirus: EBOV. Although multivalent vaccines (monovalent cocktails or vaccine vectors expressing various GPs) have and are being developed, no studies have specifically evaluated immune responses or efficacy against other Ebolavirus species (e.g., SUDV, BDBV, TAFV). Future work should focus on the development of vaccines that confer protection across all medically relevant species of the genus Ebolavirus, bearing in mind that intraspecies mutations may also arise that impact vaccine effectiveness.

[END]

[1] Url: https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010078

(C) Plos One. "Accelerating the publication of peer-reviewed science."
Licensed under Creative Commons Attribution (CC BY 4.0)
URL: https://creativecommons.org/licenses/by/4.0/


via Magical.Fish Gopher News Feeds:
gopher://magical.fish/1/feeds/news/plosone/